Intranasal gonadotropin releasing hormone agonist GnRHa for luteal phase support following GnRHa triggering a novel approach to avoid ovarian hyperstimulation syndrome in high responders

Tuesday, April 5, 2016

Authors:
Itai Bar-Hava, M.D., Yossi Mizrachi, M.D., Daphne Karfunkel-Doron, M.Sc., Yeela Omer, B.A., Liron Sheena, M.D., Nurit Carmon, Bs.C.D.R., Gila Ben-David, M.D.…

Read More

Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin releasing hormone agonist trigger

Monday, March 30, 2015
This paper describes the pathophysiology of ovarian hyperstimulation syndrome (OHSS), focusing specifically on the luteolytic benefits of the use of GnRH agonist to decrease OHSS and the possible rescue modalities available.

Read More

Luteal phase supplementation after gonadotropin releasing hormone agonist trigger in fresh embryo transfer The American versus European approaches

Monday, March 30, 2015
We describe two luteal phase support protocols after gonadotropin-releasing hormone agonist trigger: the European and the American approaches. Both concepts facilitate fresh embryo transfer with excellent reproductive outcomes in the ovarian hyperstimulation syndrome–risk patient.

Read More

Gonadotropin releasing hormone agonist triggering of final follicular maturation for in vitro fertilization

Monday, March 30, 2015
These Views and Reviews articles examine the advantages and disadvantages of gonadotropin releasing hormone (GnRH) agonist for triggering the final stage of follicular maturation in in vitro fertilization (IVF).

Read More

Calcium infusion for the prevention of ovarian hyperstimulation syndrome A double blind randomized controlled trial

Monday, December 29, 2014
Intravenous calcium infusion effectively reduced the incidence of ovarian hyperstimulation syndrome development without reduction in the pregnancy rate.

Read More

Use of gonadotropin releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome

Monday, December 29, 2014
Use of a gonadotropin-releasing hormone agonist trigger during in vitro fertilization results in similar hormone profiles, mature oocyte yield, and pregnancy outcomes in women with polycystic ovarian syndrome when compared with other high responders.

Read More

Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome OHSS animal model Implications for treatment of OHSS with dopamine receptor 2 agonists

Friday, July 25, 2014
Dopamine receptor 2 agonist prevents vascular permeability in an ovarian hyperstimulation syndrome rat model by decreasing ovarian vascular endothelial growth factor production.

Read More

Repetitive oocyte donation A committee opinion

Friday, June 20, 2014
This committee opinion describes the risks to the donor associated with oocyte donation, proposes a maximum number of oocyte donation cycles per individual, and replaces the 2008 document of the same name.

Read More

Maternal and neonatal outcomes after gonadotropin releasing hormone agonist trigger for final oocyte maturation in patients undergoing in vitro fertilization

Tuesday, May 20, 2014
Gonadotropin-releasing hormone agonist trigger does not affect obstetrical or neonatal outcomes in antagonist cycles.

Read More

Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists

Wednesday, April 30, 2014
Dopamine receptor 2 agonists inhibit VEGF secretion in a dose-dependent fashion, which is directly dependent on the amount of D2 expressed by luteinized granulosa cells.

Read More

Preventing ovarian hyperstimulation with gonadotropin releasing hormone agonist trigger Is anything perfect

Monday, March 31, 2014
Reflections on "Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol" by Fatemi et al.

Read More

A freeze all embryo strategy after in vitro maturation a novel approach in women with polycystic ovary syndrome

Monday, September 30, 2013
In vitro maturation (IVM) of oocytes followed by a “freeze-all” embryo strategy results in promising clinical outcomes in patients with polycystic ovary syndrome and circumvents the potential problem of suboptimal endometrial quality in IVM cycles.

Read More

Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization intracytoplasmic sperm injection

Wednesday, July 31, 2013
We discuss how antimullerian hormone level and antral follicle count are the best predictors for low and excessive responses in women treated with corifollitropin alfa in an antagonist protocol.

Read More

Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups An individual patient data meta analysis

Wednesday, July 31, 2013
This IPD meta-analysis demonstrates that AFC and AMH add value to age in predicting excessive response to ovarian hyperstimulation and that the accuracy of some ovarian reserve tests is affected by age.

Read More

Does the time interval between AMH serum sampling and initiation of ovarian stimulation affect its predictive ability in IVF ICSI cycles with a GnRH antagonist A retrospective single center study

Wednesday, July 31, 2013

Capsule:
A 12-month time interval between initial antimullerian hormone (AMH) measurement and commencement of ovarian stimulation does not adversely affect the ability of AMH to identify poor and excessive ovarian response.…

Read More

Antimüllerian hormone is the writing on the wall for antral follicle count

Tuesday, April 30, 2013
Reflections on "Antimüllerian hormone in GnRH antagonist cycles: Prediction of ovarian response and cumulative treatment outcome in good-prognosis patients" by Arce et al.

Read More

Biomarkers of ovarian response Current and future applications

Monday, March 18, 2013
Assessment of current strengths and limitations of antimullerian hormone and antral follicle count as ovarian biomarkers for assisted reproduction and evaluation of their future clinical applications by other health-care providers.

Read More

Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders

Wednesday, May 30, 2012
Dual trigger with GnRH agonist and low-dose hCG in high responders with peak E2 levels <4,000 pg/mL improves live birth rates.

Read More

Preventing severe OHSS has many different facets

Tuesday, May 22, 2012
Dopamine agonists, decreased FSH and hCG doses, coasting, agonist trigger, paracentesis, metformin, low-dose aspirin, anticoagulation, and possibly FSH co-trigger are measures that prevent or reduce the severity of OHSS.

Read More

Can FSH co-trigger prevent OHSS?

Tuesday, May 22, 2012
FSH co-trigger after ovarian stimulation has been shown to improve oocyte competence and a recent report suggested that the FSH co-trigger can completely prevent OHSS.

Read More

Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support

Tuesday, May 22, 2012
Intensive luteal phase support is effective in improving pregnancy rates after GnRHa trigger.

Read More

Agonist trigger: what is the best approach? Agonist trigger and low dose hCG

Tuesday, May 22, 2012
Low-dose hCG supplementation after GnRHa trigger secures the reproductive outcome and minimizes the risk of OHSS in the high-risk IVF patient.

Read More

Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos

Tuesday, May 22, 2012
Agonist triggering combined with oocyte vitrification and ET in a subsequent natural cycle avoids ovarian hyperstimulation syndrome in patients at risk and shows excellent cycle outcome.

Read More

Agonist and antagonist coast

Tuesday, May 22, 2012
GnRH antagonist cycles are associated with a lower risk of OHSS and should be the protocol of choice in high-risk patients; and coasting is a useful protocol for prevention of OHSS.

Read More

Etiology of OHSS and use of dopamine agonists

Monday, March 19, 2012
A review of the role played by VEGF on OHSS etiologyand the protective effect of dopamine agonists.

Read More

Translate »